seed
Stage
1
Investors
About
Develops weakly-acidic derivatives of existing small-molecule oncology drugs that selectively target the acidic tumor microenvironment to improve tumor selectivity and widen therapeutic windows. The company's Tumor Activated Permeability (TAP) platform chemically redesigns drugs to concentrate activity in solid tumors and reduce dose-limiting toxicities.
Explore Cytosolix, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.